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Context. Patients with adrenocortical tumors have been frequently observed to have nonadrenal neoplasia. Objective. To in-
vestigate whether patients with benign adrenocortical tumors have a higher likelihood of having nonadrenal neoplasia detected.
Design and Participants. Case-control study of patients with benign adrenocortical tumors (cases; n� 400) and normal adrenal
glands (controls; n� 400), who underwent repeated abdominal cross-sectional imaging. Main Outcomes. Primary analyses:
association between case-control status and benign abdominal neoplasia detected via cross-sectional imaging. Secondary analyses:
association between case-control status and tumors detected via other imaging modalities. Results. +e mean interval of ab-
dominal imaging was 4.7 (SD� 3.8) years for cases and 5.9 (4.8) years for controls. Cases were more likely to have detected
intraductal papillary mucinous neoplasms (IPMNs) of the pancreas (8.5% vs. 4.5%, adjusted OR� 2.22, 95% CI (1.11, 4.63))
compared with controls. In secondary analyses, cases were more likely to have detected thyroid nodules (25.5% vs. 17.0%, adjusted
OR� 1.77, 95% CI (1.15, 2.74)), hyperparathyroidism or parathyroid adenomas (3.5% vs. 1.3%, adjusted OR� 3.00, 95% CI (1.00,
11.64)), benign breast masses (6.0% vs. 3.3%, adjusted OR� 3.25, 95% CI (1.28, 8.78)), and benign prostatic hyperplasia (20.5% vs.
5.3%, adjusted OR� 3.20, 95% CI (1.14, 10.60)). Using a composite outcome, cases had higher odds of detection of the composite
of IPMN, thyroid nodules, parathyroid tumors, benign breast masses, and prostate hyperplasia (adjusted OR� 2.36, 95% CI: 1.60,
3.50) when compared with controls. Conclusions. Patients with benign adrenocortical tumors had higher odds of detected
pancreatic IPMN, as well as thyroid nodules, parathyroid tumors, benign breast masses, and prostate hyperplasia compared with
patients with normal adrenal glands. +ese associations may have important implications for patient care and healthcare
economics, regardless of whether they reﬂect incidental discoveries due to imaging detection or frequency bias, or a common risk
for developing multiple neoplasia.
1. Introduction
Benign adrenocortical tumors are common incidental
ﬁndings on abdominal computed tomography (CT) and
magnetic resonance imaging (MRI) scans [1]. As imaging
technologies are increasingly used in clinical evaluations,
these incidental ﬁndings are becoming more prevalent.
While most adrenocortical tumors are benign and presumed
to be the consequence of somatic alterations, there are rare
instances when they are driven by heritable genetic alter-
ations. For instance, adrenocortical tumors are well-known
manifestations of rare and classical genetic tumor syn-
dromes such as Li-Fraumeni, Beckwith–Wiedemann, mul-
tiple endocrine neoplasia type 1, familial adenomatous
polyposis, and Carney complex and are seen with newer
inheritable mutations. +ese classical tumor syndromes are
associated with varying morphologies of adrenocortical
neoplasia including hyperplasia, adenomas, and carcinomas,
thus linking the development of adrenal neoplasia with a
variety of extra-adrenal neoplasms via inherited mechanisms.
While the exact cause and risk factors for the high in-
cidence of adrenocortical tumors are not fully resolved,
genetic susceptibilities or common environmental exposures
may increase the overall risk of neoplasia in multiple organs.
For example, previous research on intraductal papillary
mucinous neoplasms (IPMNs) has shown that patients with
IPMNs have a higher risk for concomitant extrapancreatic
neoplasms in the absence of any syndromic diagnosis [2–4].
Similarly, patients with adrenal incidentalomas have been
observed to have a higher prevalence of thyroid nodules [5],
and patients with pituitary adenomas may be at a higher risk
for developing primary tumors at other sites [6–11]. Data
from the nationwide Swedish Family-Cancer Database
which examined the risk of subsequent primary neoplasms
after the occurrence of an endocrine gland tumor [12] found
that the risk for a second endocrine tumor was substantially
higher following the ﬁrst [12]; thereby, suggesting that the
development of a benign endocrine tumor may increase the
likelihood of developing subsequent tumors [12].
Herein, we sought to systematically investigate whether
patients with an adrenocortical tumor, but without any
known syndromic or inheritable diagnosis, were more likely
to have detected other benign abdominal or extra-abdominal
neoplasia. We conducted a case-control study among patients
who underwent repeated abdominal cross-sectional imaging
over time to assess whether having a benign adrenocortical
tumor was associated with a higher risk of detection of other
benign abdominal, and extra-abdominal, neoplasia when
compared with patients with normal adrenal glands.
2. Methods
2.1. Study Population. We designed a traditional case-con-
trol study with a cumulative sampling design. Cases and
controls were both drawn from a single institutional re-
search registry of all patients from Brigham and Women’s
Hospital, Massachusetts General Hospital, and their aﬃli-
ated partner hospitals (Figure 1). We searched this registry
for any patient with abdominal CTor MRI assessments from
1989 to 2016 (n� 234, 267) and excluded patients with
known or possible adrenal malignancy or adrenal hormonal
diagnosis such as primary aldosteronism, Cushing’s syn-
drome, congenital adrenal hyperplasia, and pheochromo-
cytoma. Cases were selected from those with diagnosis codes
for benign adrenocortical tumor (n� 1,346), while three
times as many controls were selected from those with no
adrenal tumor (n� 4,041). We completely reviewed medical
records from an arbitrary sample of 481 consecutive cases
and 513 controls, with no eﬀorts to match or pair selections,
and excluded patients with insuﬃcient information (lack of
documentation of comprehensive clinical evaluations) or if
they were <18 years old. Comprehensive clinical evaluations
included any annual physical examination, primary care or
general internal medicine visits, medical subspecialty con-
sultations, and preoperative anesthesia consultations. We
also attempted to exclude anyone with a diagnosis of any
known genetic syndrome associated with adrenocortical
adenoma, including multiple endocrine neoplasia type 1, Li-
Fraumeni, McCune Albright syndrome, Carney complex,
Beckwith-Wiedemann syndrome, familial adenomatous
polyposis, and congenital adrenal hyperplasia; however,
after careful review of medical records, no participant had
documentation of such diagnoses. We reviewed each pa-
tient’s radiology reports and considered cases as having a
benign adrenocortical tumor if the tumor had a lipid-rich
attenuation (<10 Hounsﬁeld Units) on unenhanced CT
imaging, high contrast washout on CT imaging (if available),
a marked drop in signal intensity onMRI imaging suggestive
of a lipid-rich adenoma, and/or other descriptors that are
suggestive of a benign tumor, such as “benign” or “ade-
noma” or “myelolipoma.” We excluded any potential cases
with an adrenal abnormality not consistent with a benign
adrenocortical tumor (potential malignancy, cyst, hemor-
rhage, and other nonbenign entity) and any potential
controls with evidence of an adrenal abnormality (adenoma,
thickening, metastatic disease, cyst, and hemorrhage) for a
ﬁnal study population of 400 cases with benign adreno-
cortical tumors and 400 controls with no evidence of any
adrenal abnormality.
2.2. Assessment of Baseline Characteristics. We collected
demographic information (age, sex, race, weight, height, and
derived body mass index (BMI) in kg/m2), smoking status,
and hospital aﬃliation of primary care providers from each
patient’s electronic medical record. We then determined the
ﬁrst abdominal imaging study that demonstrated benign
adrenocortical tumor or normal adrenal glands for cases and
controls, respectively. +is was considered the baseline
timepoint for adrenal morphology assessment. We collected
data on cardiovascular comorbidities (hypertension, hy-
perlipidemia, coronary artery disease, myocardial infarction,
and prediabetes or type 2 diabetes mellitus) and medications
from baseline. Hyperlipidemia was deﬁned as a documented
diagnosis and/or a low-density lipoprotein cholesterol level
of ≥150mg/dL (3.89mmol/L). Composite diabetes was
deﬁned as having either a documented diagnosis of pre-
diabetes or type 2 diabetes mellitus. Any patient with ≥2
documented hemoglobin A1c value of 5.7% to 6.4% (no
hypoglycemic agent other than metformin) was considered
to have prediabetes, and any patient with ≥2 documented
hemoglobin A1c value≥ 6.5% was considered to have type 2
diabetes mellitus.
We identiﬁed the most recent abdominal CT/MRI for all
patients and calculated the interval of imaging follow-up
deﬁned by the time elapsed from the initial to the most recent
abdominal imaging study. +e interval of imaging follow-up
was used as a proxy of the opportunity to detect the presence
of extra-adrenal abdominal neoplasia over time.
2.3. Primary Outcome Assessment: Abdominal Neoplasia
Detected via Abdominal CT/MRI. We individually reviewed
each patient’s entire collection of abdominal CT or MRI
reports in the interval of imaging follow-up for benign
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tumors of the major abdominal organs assessed including
the hepatobiliary system, pancreas, spleen, and kidneys
(Table 1). Since all included participants had repeated ab-
dominal cross-sectional imaging studies over time, the
opportunity to detect these abdominal tumors among cases
and controls was similar and the risk for imaging detection
bias deemed to be minimal.
2.4. Secondary Outcomes Assessments: Extra-Abdominal Be-
nign and Malignant Tumors. We recorded the detection of
other benign neoplasia of extra-abdominal organs from all
other available imaging modalities and the colon from co-
lonoscopy reports (Table 2). We also reviewed each patient’s
medical records for any clinical diagnoses of malignant
tumors or cancer based on physician/provider documen-
tation, reference to pathology reports, or ICD coding. +e
use of other imaging modalities besides abdominal CT/MRI
was not standardized, and the number of additional imaging
studies could not be reliably quantiﬁed using our open
electronic medical health records system; therefore, our
study design could not conﬁdently diﬀerentiate whether
extra-abdominal tumor detection was the cause or conse-
quence of imaging selection bias (for example, patients with
adrenocortical tumors may undergo more extra-abdominal
imaging studies than those without adrenocortical tumors
and thereby a greater discovery rate of incidental ﬁndings) or
true diﬀerences in tumor incidence.
2.5. Statistical Analysis. We present patients’ baseline and
demographic characteristics by case-control status using
frequencies and percentages for categorical variables and
means and standard deviations for continuous variables.
Univariate diﬀerences between baseline and demographic
characteristic by case-control status are presented using
chi-square, Fisher’s exact, and Student’s t-test tests. +e
associations between case-control status and individual
nonadrenal neoplasia were evaluated by computing uni-
variate odds ratios and their respective 95% conﬁdence
intervals (CI) and by ﬁtting multivariate logistic regression
models adjusted for age, sex, race, BMI, smoking status,
imaging interval duration (deﬁned as the time interval
between ﬁrst and last available abdominal imaging study),
and cardiovascular comorbidities (hypertension, hyper-
lipidemia, composite diabetes, coronary artery disease,
and myocardial infarction). When assessing the risk for
thyroid nodules, we also conducted sensitivity analysis
restricted to only thyroid nodules that were ≥1 cm and
thyroid nodules that had cytology conﬁrmation of benign
cells. Statistical analyses were performed by using R ver-
sion 3.0.2 (R Foundation for Statistical Computing,
Vienna, Austria).
3. Results
3.1. Baseline Demographics and Characteristics. Demographic
and clinical data of cases and controls are presented in
Table 3. Cases were more likely to be male, white, and older
in age and have a higher BMI and prevalence of diabetes
compared with controls. Both cases and controls had ap-
proximately 5 years of abdominal cross-sectional imaging
follow-up to examine for abdominal tumors, although
Patients with CT or MRI of the 
abdomen 
(n = 234,267)
No known adrenal hormonal 
diagnosis or malignancy 
(n = 223,284)
Documented diagnosis of 
adrenal tumor 
(n = 1,346)
No adrenal tumor diagnosis 
(n = 4,041)
Excluded (n = 81)
1. Age <18 (n = 2)
Adrenal abnormalities not consistent with 
benign adrenocortical adenoma 
(malignancy, cyst, hemorrhage, other non-
benign entity) (n = 68)
Insufficient information (n = 11)
Genetic tumor syndromes (n = 0)
2.
3.
4.
Charts reviewed (n = 481) Charts reviewed (n = 513)
Excluded (n = 113)
1. Age <18 (n = 1)
Adrenal abnormality (adenoma, 
thickening, metastatic disease to adrenal) 
(n = 64)
Insufficient information (n = 48)
Genetic tumor syndromes (n = 0)
2.
3.
4.
Total included
(n = 400)
Total included
(n = 400)
Figure 1: Study participant inclusion process. Participants were selected from patients who underwent abdominal CT or MRI at our
institution.
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Table 1: Outcome assessments on abdominal cross-sectional imaging.
Organ/gland Benign neoplasia Detection modality
Hepatobiliary Hepatobiliary hemangioma or adenomaHepatic cysts
Abdomen CT/MRIPancreas Intraductal pancreatic mucinous neoplasmSpleen Splenic hemangioma and cysts
Kidneys Renal angiomyolipomaRenal cysts
Table 2: Outcome assessments on other imaging modalities.
Organ/gland Benign neoplasia Detection modality
Meninges Meningioma Brain MRI
Pituitary Pituitary adenoma Head CT
+yroid +yroid nodule +yroid ultrasoundhead, neck, or chest CT
Parathyroid Hyperparathyroidism orParathyroid adenoma
Parathyroid scan with SPECT CT
Parathyroidectomy and pathology
PTH labs and clinical diagnosis
Breasts
Fibroadenoma
Papilloma Breast biopsy pathology
Other benign neoplasm Surgical excision pathology
Breast cysts
Colon Colon adenoma Colonoscopy
Prostate Benign prostatic hyperplasia Clinical diagnosisPelvic CT/MRI
Adipose Lipoma Clinical diagnosisCT/MRI
Uterus Fibroid Pelvic CT/MRI
Pelvic ultrasound
Endometrial polyp
Cervix Cervical polyp
Ovary Ovarian cyst
Table 3: Baseline demographic and clinical characteristics of cases and controls.
Characteristic Cases (adrenocortical tumor) Controls (normal adrenal) P value
Patients, n 400 400
Mean age, years (SD) 62.7 (12.9) 58.3 (14.5) <0.001
Sex
Female 268 (67.0%) 306 (76.5%) 0.001
Male 132 (33.0%) 94 (23.5%)
Race
White 294 (73.5%) 257 (64.3%) 0.043
Black 29 (7.25%) 37 (9.3%)
Hispanic 16 (4.0%) 26 (6.5%)
Others 61 (15.25%) 80 (20.0%)
Institutional primary care provider 237 (59.3%) 251 (62.8%) 0.31
Mean BMI, kg/m2 (SD) 29.5 (6.9) 28.5 (7.0) 0.047
Interval of abdominal cross-sectional imaging∗, years
(SD) 4.7 (3.8) 5.9 (4.8) 0.007
Smoking status
Nonsmoker 173 (43.3%) 216 (54.0%) 0.37
Current or past smoker 227 (56.7%) 184 (46.0%)
Comorbidity
Hypertension 242 (60.5%) 193 (48.2%) 0.41
Diabetes or prediabetes 107 (26.7%) 71 (17.8%) 0.04
Hyperlipidemia 207 (51.7%) 169 (42.2%) 0.92
Coronary artery disease 60 (15.0%) 40 (10.0%) 0.62
Myocardial infarction 29 (7.2%) 16 (4.0%) 0.50
Note. ∗Interval of imaging deﬁned as the time period between the initial and most recent cross-sectional abdominal imaging study.
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cases had a slightly shorter opportunity to detect tumors
(Table 3).
3.2. Primary Outcome: Benign Abdominal Neoplasia Detected
via Abdominal CT/MRI. +e adjusted odds ratios for each
benign nonadrenal tumor type detected via abdominal
cross-sectional imaging are presented in Table 4. Cases had
signiﬁcantly higher odds of having a pancreatic IPMN
(adjusted OR� 2.22, 95%CI: 1.11, 4.63). +ere were non-
signiﬁcant trends, further limited by small sample sizes,
suggesting that cases may be more likely to have hepatic
cysts, splenic hemangioma or cysts, renal angiomyolipoma,
and renal cysts when compared with controls.
3.3. Secondary Outcomes Assessments: Extra-Abdominal Be-
nign and Malignant Tumors. +e adjusted odds ratios for
each extra-abdominal tumor type detected via other mo-
dalities are presented in Table 5. Cases had signiﬁcantly
higher odds of having a thyroid nodule (adjusted OR� 1.77,
95%CI: 1.15, 2.74), parathyroid tumors and hyperparathy-
roidism (adjusted OR� 3.00, 95%CI: 1.00, 11.64), benign
breast tumors (adjusted OR� 3.25, 95%CI: 1.28, 8.78), and
benign prostatic hyperplasia (adjusted OR� 3.20, 95%CI:
1.14, 10.60). In sensitivity analyses restricted to only thyroid
nodules that were ≥1 cm and thyroid nodules that had cy-
tology conﬁrmation of benign cells, cases still had higher
odds of having thyroid nodules compared with controls,
although the sample size was much smaller and conﬁdence
intervals crossed 1.00 (adjusted OR� 1.72, 95%CI: 0.73, 4.13
and adjusted OR� 2.12, 95%CI: 0.87, 5.50, respectively).
+ere were no diﬀerences in the risk for any malignant
tumors or cancer (Table 6).
3.4. Composite Outcome. When using a composite outcome
for extra-adrenal neoplasia, having a benign adrenocortical
tumor (case status) was associated with signiﬁcantly higher
odds of detection of the composite of IPMN, thyroid
nodules, parathyroid tumors, benign breast masses, and
prostate hyperplasia (adjusted OR� 2.36, 95%CI: 1.60, 3.50)
when compared to patients with normal adrenal glands
(control status).
4. Discussion
It is common for adrenocortical tumors to be detected
serendipitously with abdominal imaging performed for
other reasons. While most of these tumors are benign and
sporadic, adrenocortical tumors are also phenotypic man-
ifestations of certain classical inheritable tumor syndromes.
+e observations of our current study suggest that even in
the absence of known syndromic neoplasia, patients with
benign-appearing adrenocortical tumors may be more likely
to have detected IPMNs, as well as benign neoplasia of the
thyroid, parathyroid, breast, and prostate. Whether these
tumors of diﬀerent organs were incidentally detected due to
imaging performance bias or imaging detection bias, or are
causally linked through a common pathway, could not be
assessed with the current study design; however, the ultimate
observation has important implications for the clinical care
of patients, regardless of the reason for the detection dif-
ference. +e possibility that patients with an incidentally
detected adrenocortical tumor are more likely to have de-
tected extra-adrenal tumors (either due to excessive scrutiny
of available images or via additional imaging studies or-
dered) could have major implications for healthcare
spending and patient care. Alternatively, the possibility that
there is a casual link between adrenocortical tumors and
these extra-adrenal tumors, as discussed below, may also
have important implications, given how common adreno-
cortical tumors are.
+e association between having adrenocortical tumors
and IPMNs was robust and independent of numerous po-
tential confounders. Both cases and controls underwent
repeated cross-sectional abdominal imaging over time
wherein controls were imaged over a longer interval of time,
thereby providing greater opportunity to detect potential
tumors. In this regard, the observation that IPMNs are more
likely to be detected among cases (patients with adreno-
cortical tumors) is unlikely to be due to detection or imaging
bias. In this regard, our ﬁndings support prior studies
demonstrating that having one endocrine neoplasm may
increase the risk of having other tumors [12] and that having
an IPMN is associated with having other nonpancreatic
tumors [2–4]. In contrast, our secondary observations that
adrenocortical tumors were also associated with a higher
likelihood of having benign tumors of the thyroid, para-
thyroid, breast, and prostate were less robust. +e study was
designed with standardized abdominal cross-sectional im-
aging between cases and controls, and therefore, the con-
ﬁdence and consistency in the detection of abdominal
tumors was high. However, the study design could not
standardize the indications or frequency/number of imaging
studies focused on the neck, chest, pelvis, and other sites.
Since we could not reliably account for these factors, it is
possible that the association of having tumors of the thyroid,
parathyroid, breast, and prostate among individuals with
adrenocortical tumors may be due to imaging performance
and/or detection bias, wherein patients with adrenocortical
tumors could have undergone more imaging studies with
closer scrutiny for other tumors, rather than a true causal
link.
Regardless of the mechanistic explanation for the as-
sociation, these observations highlight an important clinical
phenomenon: patients with adrenocortical tumors are either
more likely to have detected, or more likely to develop,
benign neoplasia of the pancreas, thyroid, parathyroid,
breast, and/or prostate. It may certainly be possible that the
incidental detection of one tumor, directly or indirectly,
leads to more imaging procedures that result in the detection
of other incidental tumors (a factor our study design could
not reliably quantify). Whether this is of beneﬁt to patients
(i.e., early detection of potentially harmful processes) or a
burden to patients and healthcare spending (i.e., excessive
detection of benign and clinically innocuous tumors) is an
important query for the medical ﬁeld to consider. Future
work should therefore focus on elucidating whether the
International Journal of Endocrinology 5
Table 4: Risk for benign abdominal neoplasia detected via abdominal cross-sectional imaging.
Benign abdominal neoplasm Cases (adrenocorticaltumor) Controls (normal adrenal) OR (95% CI) AOR (95% CI)
∗
n 400 400
Hepatobiliary hemangioma or adenoma 26 (6.5%) 19 (4.8%) 1.39 (0.76, 2.59) 1.30 (0.61, 2.79)
Hepatic cyst 109 (27.3%) 91 (22.8%) 1.27 (0.93, 1.75) 1.44 (0.98, 2.17)
Intraductal pancreatic mucinous
neoplasm 34 (8.5%) 18 (4.5%) 1.97 (1.11, 3.62) 2.22 (1.11, 4.63)
Splenic hemangioma and cyst 16 (4.0%) 10 (2.5%) 1.62 (0.74, 3.75) 4.46 (0.92, 7.01)
Renal angiomyolipoma 9 (2.3%) 4 (1.0%) 2.28 (0.73, 8.46) 4.50 (0.94, 33.10)
Renal cyst 216 (54.0%) 167 (41.8%) 1.64 (1.24, 2.16) 1.25 (0.86, 1.81)
Note. +e unadjusted and adjusted∗ odds ratio for patients with benign adrenocortical tumors (cases) compared with those with normal adrenal glands
(controls) are presented along with 95% conﬁdence intervals for each benign abdominal neoplasm. AOR: adjusted odds ratio; ∗adjusted for age, sex, race,
smoking status, BMI, duration imaging interval, hypertension, hyperlipidemia, composite diabetes (diabetes or prediabetes), coronary artery disease, and
myocardial infarction.
Table 5: Risk for benign neoplasia detected via other modalities.
Other benign neoplasm Cases (adrenocorticaltumor)
Controls (normal
adrenal) OR (95% CI) AOR (95% CI)
∗
n 400 400
Meningioma 11 (2.8%) 5 (1.3%) 2.23 (0.80, 7.14) 2.45 (0.61, 12.42)
Pituitary adenoma 4 (1.0%) 5 (1.3%) 0.80 (0.20, 3.03) 0.64 (0.07, 4.50)
+yroid nodule 102 (25.5%) 68 (17.0%) 1.67 (1.19, 2.36) 1.77 (1.15, 2.74)
+yroid nodule≥ 10mm 66 (16.5%) 35 (8.8%) 1.88 (0.98, 3.63) 1.72 (0.73, 4.13)
FNA benign thyroid 35 (8.8%) 17 (4.3%) 1.62 (0.82, 3.29) 2.12 (0.87, 5.50)
Hyperparathyroidism or parathyroid
adenoma 14 (3.5%) 5 (1.3%) 2.87 (1.08, 8.93) 3.00 (1.00, 11.64)
Benign breast Mass 16 (6.0%) 10 (3.3%) 1.62 (0.73, 3.75) 3.25 (1.28, 8.78)
Breast cyst 24 (9.0%) 46 (15.0%) 0.49 (0.29, 0.81) 0.59 (0.31, 1.10)
Colon adenoma 164 (41.0%) 136 (34.0%) 1.34 (1.01, 1.79) 1.15 (0.80, 1.65)
Benign prostatic hyperplasia 27 (20.5%) 5 (5.3%) 5.71 (2.37, 17.00) 3.20 (1.14, 10.60)
Lipoma 53 (13.3%) 46 (11.5%) 1.17 (0.77, 1.79) 1.08 (0.63, 1.83)
Fibroid 86 (32.1%) 95 (31.0%) 0.88 (0.63, 1.22) 1.36 (0.89, 2.12)
Endometrial polyp 25 (9.3%) 35 (11.4%) 0.89 (0.40, 1.79) 0.78 (040, 1.49)
Cervical polyp 22 (8.2%) 31 (10.1%) 0.69 (0.39, 1.21) 0.92 (0.46, 1.82)
Ovarian cyst 54 (20.1%) 83 (27.1%) 0.60 (0.41, 0.86) 1.40 (0.85, 2.34)
Note. +e unadjusted and adjusted∗ odds ratio for patients with benign adrenocortical tumors (cases) compared with those with normal adrenal glands
(controls) are presented along with 95% conﬁdence intervals for each benign neoplasm. AOR: adjusted odds ratio; ∗adjusted for age, sex, race, smoking status,
BMI, duration imaging interval, hypertension, hyperlipidemia, composite diabetes (diabetes or prediabetes), coronary artery disease, and myocardial
infarction.
Table 6: Risk for malignant tumors.
Malignancy Cases (adrenocortical tumor) Controls (normal adrenal) OR (95% CI) AOR (95% CI)∗
Gastrointestinal cancer 22 (5.5%) 29 (7.3%) 0.74 (0.42, 1.32) 0.84 (0.42, 1.69)
Renal/bladder cancer 14 (3.5%) 18 (4.5%) 0.77 (0.38, 1.57) 0.98 (0.41, 2.33)
Breast cancer 36 (9.0%) 50 (12.5%) 0.69 (0.44, 1.08) 0.83 (0.47, 1.46)
Lung cancer 23 (5.8%) 12 (3.0%) 2.0 (0.97, 4.02) 1.73 (0.77, 4.10)
Brain cancer 2 (0.5%) 4 (1.0%) 0.45 (0.09, 2.73) NA
Endocrine cancer 13 (3.3%) 11 (2.8%) 1.28 (0.53, 2.68) 1.53 (0.60, 4.11)
Hematologic cancer 15 (3.8%) 24 (6.0%) 0.61 (0.31, 1.18) 0.59 (0.27, 1.25)
Melanoma/sarcoma 4 (1.0%) 14 (3.5%) 0.28 (0.09, 0.85) 0.19 (0.05, 0.59)
Gynecologic cancer 15 (3.7%) 20 (5.0%) 0.74 (0.37, 1.47) 0.57 (0.24, 1.26)
Prostate/testicular cancer 13 (3.2%) 16 (4%) 0.80 (0.38, 1.70) 0.49 (0.16, 1.50)
Other cancer 3 (0.8%) 2 (0.5%) 1.50 (0.25, 9.04) NA
Note. +e unadjusted and adjusted∗ odds ratio for patients with benign adrenocortical tumors (cases) compared with those with normal adrenal glands
(controls) are presented along with 95% conﬁdence intervals for eachmalignancy. AOR: adjusted odds ratio; ∗adjusted for age, sex, race, smoking status, BMI,
duration imaging interval, hypertension, hyperlipidemia, composite diabetes (diabetes or prediabetes), coronary artery disease, and myocardial infarction.
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imaging detection of these tumors are a boon or burden on
patient care and healthcare economics and/or whether there is
a common genetic or other causal link for these observations.
Possible biological explanations for our ﬁndings include
potential genetic predispositions involved in a common
neoplastic pathway may lead to greater risk of developing
multiple benign neoplasia. +ese genetic variants may in-
volve known genes that are already implicated in rare tumor
syndromes (i.e., MEN1 and TP53) or novel and complex
polygenic variation that is currently not well understood. It
has been well demonstrated that there is a high rate of
β-catenin alterations in adrenocortical tumors suggesting
that activation of the Wnt/β-catenin signaling pathway may
play a major role in adrenocortical tumorigenesis [13–15];
however, this abnormality also exists in nonadrenal tumors.
In a study by Chetty et al., 7 of 18 (39%) cases of benign and
malignant IPMNs displayed abnormal Wnt-signaling
pathway with abnormal localization of β-catenin [16].
Bjo¨rklund et al. demonstrated that all 47 (100%) analyzed
parathyroid tumors, and all 84 (100%) parathyroid tumors in
a subsequent study, demonstrated abnormal β-catenin ac-
cumulation [17, 18]. Similarly, Whitaker et al. found ab-
normal nuclear accumulation of β-catenin in 40% of the 80
samples of benign prostatic hyperplasia [19]. Hence, germline
or other acquired abnormalities in the Wnt/β-catenin path-
way may represent one potential cause of acquiring a higher
collective risk for developing these tumors.
Another explanation may be that there exists a higher
frequency of genetic and phenotypic variants of the known
classical tumor syndromes within the general population.
Vouillarmet et al. reported a patient with a hormonally
active adrenocortical tumor before any symptoms of familial
adenomatous polyposis appeared [20]. Similarly, Talaei et al.
reported a patient presenting with a right adrenocortical
tumor and an incidentally discovered pituitary adenoma
who was subsequently diagnosed with Carney complex
suggesting potentially greater phenotypic heterogeneity [21].
While these are isolated case reports, it may be possible that
there are individuals without the “classical,” or severe,
presentations of the known inherited neoplasia syndromes,
or with less penetrant manifestations that evade formal
diagnosis.
Other possible explanations may include environmental
risk factors leading to increased risk for multiple benign
neoplasia. While we did not detect a signiﬁcant diﬀerence in
smoking history, we could not evaluate other lifestyle habits
such as physical activity, diet, alcohol use, and other envi-
ronmental variables. Our data show signiﬁcantly greater
BMI and diabetes prevalence status in individuals with
adrenal tumors. Previous studies have examined the re-
lationship between obesity, insulin resistance, and tumori-
genesis. While incompletely understood, insulin resistance
may promote tumorigenesis through increased levels of
insulin, insulin-like growth factors, and sex steroids and
their role in energy intake, increased cellular proliferation,
and suppression of apoptosis [22–27]. Studies have also
suggested that high BMI and adiposity result in greater
inﬂammation that may promote tumorigenesis [25–29], and
associations between high BMI and diabetes with increased
risk for colon, liver, pancreatic, kidney, and endometrial
cancer have been reported [25–33]. While these studies
examined malignant tumors, it may be possible that the
hormonal milieu and cellular environment of individuals
with diabetes and high BMI may also increase the risk for
benign neoplasia and hyperplasia.
Our study must be interpreted within the context of our
study design. Bias is an important consideration in case-
control studies.We attempted to limit selection bias by using
arbitrary selection of consecutive patients from the same
institutional database. Diﬀerences in the imaging frequency
of abdominal and extra-abdominal organs represent another
source of bias, as discussed extensively above. +e frequency
of abdominal imaging was not standardized; however, the
use of cross-sectional abdominal imaging was required, and
the imaging interval over time permitted ample opportunity
to detect abdominal tumors in both cases and controls. In
fact, we observed that even though patients with normal
adrenal glands (controls) were imaged over a longer interval
of time, patients with adrenal tumors (cases) had signiﬁ-
cantly higher odds of having abdominal pancreatic IPMNs.
We also observed nonsigniﬁcant trends suggesting a higher
risk for several other benign tumors and masses; larger
sample sizes would be needed to ascertain whether these
trends are suggestive of true associations. Given the ob-
servational and retrospective nature of this study, the in-
dications for various types of diagnostic imaging in our
secondary analyses were not controlled, and it is possible
that cases were subjected to more imaging opportunities
than controls. We could not conﬁdently quantify the
number of imaging tests each patient underwent since pa-
tients may have undergone some testing outside of our
health system; however, even if cases underwent more
frequent imaging, the interpretations of our ﬁndings still
implicate that patients with adrenocortical tumors have a
higher likelihood of detection of benign extra-adrenal
neoplasia. Our study was not designed to determine the
directionality or temporal relationship between develop-
ment of adrenal neoplasia and extra-adrenal neoplasia, or
the involvement of another factor (genetic or environ-
mental). +erefore, we cannot make ﬁrm conclusions re-
garding the direction, timing, or pathogenic cause of these
ﬁndings. Because our observations were based on standard
clinical care, patients did not undergo repeated evaluations
for subclinical hypercortisolism, or other adrenal hormone
excess, which can contribute to cardiometabolic diseases. In
addition, while patients in our study did not have clinical
diagnoses to indicate known genetic tumor syndromes, we
did not have the ability to conduct systematic genetic testing
to conﬁrm this, nor evaluate potential genetic contributions
to our ﬁndings. Lastly, while we adjusted for all potential
covariates available to us, there remains a risk for residual
confounding.
In conclusion, we observed that having benign adre-
nocortical neoplasia was associated with a signiﬁcantly
higher likelihood of detection of pancreatic IPMN and other
benign neoplasia or hyperplasia of the thyroid, parathyroid,
breast, and prostate, in the absence of a diagnosis of a known
genetic tumor syndrome. It is possible that these ﬁndings are
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the result of detection or imaging bias resulting in increased
frequency of incidental tumor detection, mild or common
pathogenic variants of rare genetic syndromes in the pop-
ulation, and/or unrecognized environmental exposures.
Regardless of the underlying cause of this observation, these
ﬁndings have important implications in determining the
oncologic risk proﬁle and clinical management of patients
found to have adrenocortical adenomas.
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